US20100068309A1 - Method of evaluating skin barrier function, method of screening material for enhancing skin barrier function using the evaluating method, the material for enhancing skin barrier function, and cosmetic containing the material for enhancing skin barrier function - Google Patents

Method of evaluating skin barrier function, method of screening material for enhancing skin barrier function using the evaluating method, the material for enhancing skin barrier function, and cosmetic containing the material for enhancing skin barrier function Download PDF

Info

Publication number
US20100068309A1
US20100068309A1 US12/516,483 US51648307A US2010068309A1 US 20100068309 A1 US20100068309 A1 US 20100068309A1 US 51648307 A US51648307 A US 51648307A US 2010068309 A1 US2010068309 A1 US 2010068309A1
Authority
US
United States
Prior art keywords
barrier function
skin barrier
enhancing skin
metal ions
permeability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/516,483
Inventor
Shohei Kuroda
Takuya Yamamoto
Yuko Saeki
Masumi Kurasawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pola Chemical Industries Inc
Original Assignee
Pola Chemical Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pola Chemical Industries Inc filed Critical Pola Chemical Industries Inc
Assigned to POLA CHEMICAL INDUSTRIES INC. reassignment POLA CHEMICAL INDUSTRIES INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KURASAWA, MASUMI, KURODA, SHOHEI, SAEKI, YUKO, YAMAMOTO, TAKUYA
Publication of US20100068309A1 publication Critical patent/US20100068309A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH

Definitions

  • the present invention relates to a method of evaluating skin barrier function, a method of screening material for enhancing skin barrier function using the evaluating method, the material for enhancing skin barrier function, and a cosmetic containing the material for enhancing skin barrier function.
  • the present invention has been made under the above-mentioned circumstances, and it is an object of the present invention to provide a technology for developing an excellent material for enhancing skin barrier function, and to develop and provide a cosmetic having excellent ability to enhance the skin barrier function based on the technology.
  • the inventors of the present invention found that a material for enhancing skin barrier function that is excellent as a cosmetic material can be obtained by screening the material using movement of metal ions as an index, in particular, calcium ions that affect differentiation of a horny layer cell, from dermis or tissue equivalent for the dermis to horny layer cell, and thus completed the present invention. That is, the present invention is as follows.
  • the present invention it is possible to provide a technology for developing an excellent material for enhancing skin barrier function, and to develop and provide a cosmetic having excellent ability to enhance the skin barrier function based on the technology.
  • FIG. 1 Graphs each showing a relationship between an added metal ion concentration and a permeability coefficient obtained in Example
  • FIG. 2 Graphs each showing a relationship between TER and the permeability coefficient obtained in Example 1.
  • FIG. 3 Graphs each showing a comparison result of media obtained in Example 2.
  • FIG. 4 A graph showing results according to Example 3.
  • FIG. 5 Graphs each showing results according to Examples 4 to 7.
  • FIG. 6 A graph showing results according to Examples 8, 10, and 11.
  • FIG. 7 A graph showing results according to Example 9.
  • FIG. 8 A graph showing the results of Examples 12 and 13.
  • a method of evaluating skin barrier function is characterized by using permeability of metal ions through an epidermal cell layer as an index.
  • the method uses permeability from a basal layer to a horny layer as the index.
  • permeability refers to both an ability of a substance to enter into and exit from cells and an ability of a substance to pass through cells. It is evaluated that the higher the permeability of the metal ions, the lower the skin barrier function.
  • the evaluating method for example, can be performed as follows:
  • the epidermal cells may be epidermal cells of any sites, and examples thereof include a foreskin of a newborn baby and a breast of an adult woman.
  • the epidermal cells may be commercially available epidermal cells. Examples of the commercially available epidermal cells include normal human newborn foreskin epidermal keratinocytes (NHEK) (manufactured by Kurabo Industries Ltd.).
  • the epidermis is composed of a basal layer, a prickle cell layer, a granule layer, and a horny layer. In the evaluating method of the present invention, cells of all of the layers may be used, but basal layer cells are preferably used.
  • the cell culture conditions or the like may be general conditions.
  • the culture time under a metal ion loaded condition is generally about one to three hours.
  • the concentration of loaded metal ions is generally about 5 to 10 mM.
  • Such evaluation may be performed in vitro for, e.g., three-dimensionally cultured epidermal cells as described above or for living experimental animals. Meanwhile, the evaluating method of the present invention may be used to uniformize a barrier function by measuring the value of the movement of metal ions for each prepared culture product to determine homogeneity.
  • the evaluating method of the present invention can be used for evaluating whether a test substance acts for enhancing or inhibiting skin barrier function in a formation of an epidermal cell membrane by comparing the cases of culture of normal human epidermal cells in presence and absence of the test substance.
  • the evaluating method of the present invention can be applied to screening of a component for improving skin barrier function.
  • the screening can be performed by: defining a value calculated by the following expression: (1 ⁇ metal ion permeation ratio in the presence of a test substance/metal ion permeation ration in the absence of a test substance) ⁇ 100; and evaluating that the larger the value, the higher the ability to improve skin barrier function.
  • the method can discriminate that the higher the ability to inhibit permeability of calcium or the like, the higher the ability to improve the skin barrier function.
  • Such inhibition of permeation can control the concentration of ion such as calcium in the epidermis to correct the concentration gradient to an appropriate value.
  • the screening described above may be performed by using normal epidermal cells derived from human or normal epidermal cells derived from an animal other than human.
  • epidermal cells having specific properties are created by transforming the cells by masking a part of genes with complementary genes or introducing another gene into the cells using a vector or the like, and the epidermal cells may be used for the screening as in the above.
  • the metal ions to be used for the evaluation are not particularly limited as long as they are unevenly distributed in a living body, and are particularly preferably alkaline earth metals, and of those, a calcium and/or magnesium ion is preferred. Most preferred is a calcium ion. This is because the calcium ion acts as a cell differentiation factor in epidermal cells, and is a metal ion to be controlled in a condition that skin barrier function is normal, and excess permeation of the calcium ion in an epidermal cell layer is an absolute evidence of the skin barrier dysfunction.
  • the efflux of the calcium ion from the epidermis,that is, excess passage of the calcium ion may prevent the maturation of horny layer cells and the formation of strong skin barrier function.
  • a material to prevent such phenomenon can improve the barrier function in the epidermis and promote the maturation of healthy horny layer cells in a horny cell layer, resulting in improvement of the skin barrier function.
  • the labeling means may be used to clarify distribution of a metal ion such as a calcium ion in a living body.
  • a metal ion such as a calcium ion in a living body.
  • such means maybe employed.
  • a preferable label for the calcium ion include a dye such as Arsenazo III or a salt thereof.
  • a preferable label for a magnesium ion include Xylidyl blue I.
  • the concentration of the label is 0.001 mM to 1,000 mM.
  • An area where the label is localized is considered as an area where a metal ion such as calcium is also localized.
  • an area where the concentration of the label is higher is considered as an area where the concentration of the metal ion such as a calcium ion is higher.
  • a material for enhancing skin barrier function of the present invention is a material for enhancing skin barrier function, which is judged to be effective by a method of screening material for enhancing the skin barrier function.
  • the material is preferably includes a component that significantly inhibits the transference of calcium from the dermis, tissue equivalent for dermis, or deep part of the epidermis to the horny layer or tissue equivalent for horny layer in the presence of a test substance compared with the case in the absence of the test substance.
  • Such an action is dose-dependent, and the material is preferably blended into a cosmetic in an amount within a range to give dose dependency.
  • the dose for the action varies depending on type of materials, and is for example, 0.01 mM to 50 mM, and in terms of an animal or plant extract, 0.001 to 10% (final concentration in use). If the dose is within the range, the material can act as an adjuster for a calcium ion in the horny layer and improve the barrier function in the horny layer.
  • Specific preferred examples of the material for enhancing skin barrier function which serves as an adjuster for a calcium ion, include: solvent-removed products or fractionated products of extracts obtained from peels of plants of the genus Citrus in the family Rutaceae such as orange, Citrus tachibana, and Citrus aurantium with a polar solvent, preferably an aqueous solution of 30 to 70% ethanol; solvent-removed products or fractionated products of extracts obtained from seeds of plants of the genus Pimpinella in the family Apiaceae such as Japanese honewort and fennel with a polar solvent, preferably an aqueous solution of 30 to 70% ethanol; extract, preferably, solvent-removed products or fractionated products of extracts obtained from flowers or flower buds of plants of the genus Bellis in the family Compositae such as Bellis perennis with a polar solvent, preferably an aqueous solution of 30 to 70% ethanol; royal jerry or a protein thereof
  • Such a component is blended into a cosmetic in an amount of 0.01 to 10% by mass, more preferably 0.05 to 1% by mass based on the total amount of the cosmetic.
  • the reason is as follows: if the amount is too small, the above-mentioned effects cannot be obtained in some cases, while if the amount is too large, the amount of the component delivered to the epidermis may reach a plateau, and freedom of the prescription may be unnecessarily impaired.
  • the cosmetic of the present invention is characterized by containing a strengthening material of the skin barrier function.
  • the cosmetic of the present invention can contain optional ingredients used commonly in a cosmetic as well as those ingredients.
  • Preferred examples of such an optional component include: oils/waxes such as macadamia nut oil, avocado oil, corn oil, olive oil, rapeseed oil, sesame oil, castor oil, safflower oil, cottonseed oil, jojoba oil, coconut oil, palm oil, liquid lanolin, cured coconut oil, cured oil, Japan wax, cured castor oil, beeswax, candelilla wax, carnauba wax, ibota wax, lanolin, reduced lanolin, hard lanolin, and jojoba wax; hydrocarbons such as liquid paraffin, squalane, pristane, ozokerite, paraffin, ceresin, vaseline, and microcrystalline wax; higher fatty acids such as oleic acid, isostearic acid, lauric acid
  • Red No. 202 Red No. 228, Red No. 226, Yellow No. 4, Blue No. 404, Yellow No. 5, Red No. 505, Red No. 230, Red No. 223, Orange No. 201, Red No. 213, Yellow No. 204, Yellow No. 203, Blue No. 1, Green No. 201, Purple No. 201, and Red No.
  • organic fine particles such as polyethylene powder, polymethyl methacrylate powder, nylon powder, and organopolysiloxane elastomer
  • ultraviolet absorbents such as a p-aminobenzoate-based ultraviolet absorbent; an anthranilate-based ultraviolet absorbent; a salicylate-based ultraviolet absorbent; a cinnamate-based ultraviolet absorbent; a benzophenone-based ultraviolet absorbent; a sugar-based ultraviolet absorbent; 2-(2′-hydroxy-5′-t-octylphenyl) benzotriazole, and 4-methoxy-4′-t-butyldibenzoylmethane; lower alcohols such as ethanol and isopropanol; vitamins such as vitamin A or derivatives thereof, vitamin B types such as vitamin B6 hydrochloride, vitamin B6 tripalmitate, vitamin B6 dioctanoate, vitamin B2 or derivatives thereof, vitamin B12, and vitamin B15 or derivatives thereof, vitamin E types
  • a cosmetic of the present invention can be produced by processing a material for enhancing skin barrier function, which is an essential component and serves as an adjuster for a calcium ion in the horny layer, together with the above-mentioned optional components in accordance with a conventional method. It is particularly preferable to accurately deliver the material for enhancing skin barrier function to the epidermis in an appropriate manner. Therefore, the material may be incorporated into a delivery compartment such as liposome, double-membrane vesicle, or fat globule such delivery compartment that carries a material for enhancing skin barrier function may be incorporated into a cosmetic.
  • the cosmetic particularly preferably contains such a delivery compartment.
  • a formulation of the cosmetic is not particularly limited as long as it is generally known, and preferable examples of the cosmetic include lotion cosmetics, milky lotion cosmetics, cream cosmetics, essence cosmetics, pack cosmetics, under makeup cosmetics, and foundations, and of those, particularly preferable are lotion cosmetics, milky lotion cosmetics, cream cosmetics, essence cosmetics, pack cosmetics, etc.
  • NHEK normal human epidermal keratinocytes
  • a Transwell manufactured by Corning Incorporated (diameter 12 mm, polyethylene terephthalate, 0.4 ⁇ m pore) was placed on a Millicell (registered trademark) tissue culture plate (manufactured by Millipore), and the above-mentioned culture medium was added in amounts of 1.5 ml to the lower layer and 0.5 ml to the upper layer.
  • the normal human epidermal keratinocytes were inoculated at 1 ⁇ 10 5 /cm 2 and cultured for additional 72 hours. After the cells were confirmed to be confluent, the culture medium was exchanged for a 1.45-mM Ca-containing Humedia KG2 medium, and the cells were cultured for additional 96 hours.
  • TERs transepithelial electrical resistance
  • the prepared solutions described in Table 1 were each added to the basolateral side in an amount of 1.5 ml, and the prepared solutions described in Table 1 were each added to the apical side in an amount of 0.5 ml.
  • Static cultures were each performed at 37° C. in 5% carbon dioxide atmosphere for two hours, and the solutions of the apical and basolateral sides were each recovered.
  • NHEK normal human epidermal keratinocytes
  • a Transwell manufactured by Corning Incorporated (diameter 12 mm, polyethylene terephthalate, 0.4 ⁇ m pore) was placed on a Millicell (registered trademark) tissue culture plate (manufactured by Millipore), and the above-mentioned culture medium was added in amounts of 1.5 ml to the lower layer and 0.5 ml to the upper layer.
  • the normal human epidermal keratinocytes were inoculated at 1 ⁇ 10 5 /cm 2 and cultured for additional 72 hours. After the cells were confirmed to be confluent, the culture medium was exchanged for a 1.45 mM Ca-containing Humedia KG2 medium, and the cells were cultured for additional 96 hours.
  • TERs were measured, and the prepared solution described in Table 1-1 (e) or Table 1-2 (e) was added to the basolateral side in an amount of 1.5 ml, and the prepared solution described in Table 1-1 or Table 1-2 was each added to the apical side in an amount of 0.5 ml. Static cultures were each performed at 37° C.
  • FIG. 1 Relationships between added metal ion concentrations and permeability coefficients are shown in FIG. 1 .
  • TERs were found to be negatively correlated with permeability coefficients, and the fact supports that the permeability coefficients are values correlated with skin barrier function.
  • FIG. 2 The results are shown in FIG. 2 .
  • calcium was selected as a metal ion to be added to compare calcium permeability coefficients and magnesium permeability coefficients in a low-calcium medium cultured cells (shown as Ca ⁇ in FIG. 3 ) (0.15 mM) and in a high-calcium medium cultured cells (shown as Ca+ in FIG. 3 ) (1.45 mM). That is, frozen normal human epidermal keratinocytes (NHEK) (manufactured by Kurabo Industries Ltd.) were thawed and cultured in a 0.15 mM Ca-containing culture medium (Humedia-KG2; manufactured by Kurabo Industries Ltd.) at 37° C. in 50% carbon dioxide atmosphere.
  • NHEK frozen normal human epidermal keratinocytes
  • NHEK normal human epidermal keratinocytes
  • Example 1 Cells obtained by three-dimensional culture by the procedure of Example 1-1) were cultured in the presence of 10 -1 % of the Pimpinella extract 1 at a calcium loaded concentration of 5 mM, and a calcium ion was stained by the procedure of Example 1-3) and an absorbance was measured. A test substance having a concentration of 0 was defined as a control, and a calcium ion permeation ratio was calculated. The results are shown in FIG. 5 . The results revealed that Pimpinella extract 1 had ability to inhibit the transference of a calcium ion from the dermis/the deep part of the epidermis to the horny cell layer.
  • Example 4 To study inhibition of the transference of a calcium ion, the same procedure as in Example 4 was repeated except that L-carnitine (manufactured by Sigma) was used instead of the Pimpinella extract 1. The results are shown in FIG. 5 . The results revealed that L-carnitine had ability to inhibit the transference of a calcium ion from the dermis/the deep part of the epidermis to the horny cell layer.
  • Example 4 To study inhibition of the transference of a calcium ion, the same procedure as in Example 4 was repeated except that hydrolyzed royal jelly protein (“Royal Biocyte PX”, manufactured by Katakura Chikkarin Co., Ltd.) was used instead of the Pimpinella extract 1. The results are shown in FIG. 5 . The results revealed that the hydrolyzed royal jelly protein had ability to inhibit the transference of a calcium ion from the dermis/the deep part of the epidermis to the horny cell layer.
  • Hydrolyzed royal jelly protein (“Royal Biocyte PX”, manufactured by Katakura Chikkarin Co., Ltd.) was used instead of the Pimpinella extract 1.
  • the results are shown in FIG. 5 .
  • Palmaria extract 1 had ability to inhibit the transference of a calcium ion from the dermis/the deep part of the epidermis to the horny cell layer.
  • NHEK normal human epidermal keratinocytes
  • a 0.15 mM Ca-containing culture medium Humedia-KG2; manufactured by Kurabo Industries Ltd.
  • a Transwell manufactured by Corning Incorporated (diameter 12 mm, polyethylene terephthalate, 0.4 ⁇ m pore) was placed on a Millicell tissue culture plate (manufactured by Millipore), and the above-mentioned culture medium was added in amounts of 0.5 ml to the upper layer and 1.5 ml to the lower layer.
  • the normal human epidermal keratinocytes were inoculated at 1 ⁇ 10 5 /cm 2 and cultured for additional 72 hours.
  • the culture medium was exchanged for a 1.45 mM Ca-containing Humedia KG2 medium, and the cells were cultured for additional 96 hours. Thereafter, the medium was exchanged for a culture medium containing 10 ⁇ 4 v/v % ⁇ , ⁇ -bis( ⁇ -N-lauroylglutamyl)lysine (Pellicer L-30 (registered trademark) (hereinafter, referred to as Pellicer); manufactured by Asahi Kasei Corporation), and TERs were measured.
  • Pellicer registered trademark
  • the culture was further continued, and one, two, three, and four days later, TERs were measured.
  • the graph shows changes with time in TER (transepitherial electrical resistance) values ( ⁇ cm 2 ) after certain lengths of time with respect to TER values at the time of addition of the extract.
  • the results are shown in FIG. 7 .
  • calcium ion permeability coefficients were measured in accordance with the procedure of Example 1, and it was found that the coefficients were inversely correlated with the changes in the TERs.
  • Example 4 To study inhibition of the transference of a calcium ion, the same procedure as in Example 4 was repeated except that ⁇ , ⁇ -glutamyl lysine was used instead of the Pimpinella extract 1. The results are shown in FIG. 6 . The results revealed that ⁇ , ⁇ -glutamyl lysine had ability to inhibit the transference of the calcium ion from the dermis/the deep part of the epidermis to the horny cell layer.
  • NHEK normal human epidermal keratinocytes
  • a 0.15 mM Ca-containing culture medium Humedia-KG2; manufactured by Kurabo Industries Ltd.
  • a Transwell manufactured by Corning Incorporated (diameter 12 mm, polyethylene terephthalate, 0.4 ⁇ m pore) was placed on a Millicell tissue culture plate (manufactured by Millipore), and the above-mentioned culture medium was added in amounts of 0.5 ml to the upper layer and 1.5 ml to the lower layer.
  • the normal human epidermal keratinocytes were inoculated at 1 ⁇ 10 5 /cm 2 and cultured for additional 72 hours. After the cells were confirmed to be confluent, the culture medium was exchanged for a 1.45 mM Ca-containing Humedia KG2 medium, and the cells were cultured for additional 96 hours. Thereafter, the medium was exchanged for a culture medium containing 10 ⁇ 5 v/v % the Coptis japonica extract 1, and TERs were measured. The culture was further continued, and one, two, three, and four days later, TERs were measured.
  • NHEK normal human epidermal keratinocytes
  • the graph shows changes with time in TER (transepitherial electrical resistance) values ( ⁇ cm 2 ) after certain lengths of time with respect to TER values at the time of addition of the extract.
  • TER transepitherial electrical resistance
  • FIG. 8 The results are shown in FIG. 8 .
  • calcium ion permeability coefficients were measured in accordance with the procedure of Example 1, and it was found that the coefficients were inversely correlated with the changes in the TERs.
  • Example 12 The same procedure as in Example 12 was repeated except that a dried product of the peel of Citrus aurantium of the genus Citrus in the family Rutaceae was used instead of the rhizome of Coptis japonica, to thereby yield a Citrus aurantium peel extract 1.
  • the extract was evaluated by measuring changes in resistance values caused by inhibition of the transference of the calcium ion in the same way as in Example 12. The results are shown in FIG. 8 . The results revealed that the Citrus aurantium peel extract 1 had excellent ability to inhibit calcium.
  • a cosmetic of the present invention was produced. Specifically, according to the following prescriptions, cosmetic of the present invention was prepared as milky lotions. That is, the components shown in (A) were mixed and heated to 80° C. On the other hand, the components shown in (B) were heated to 80° C. The mixture (B) was added to the mixture (A), and the whole was emulsified by stirring and neutralized by adding the components shown in (C), followed by cooling to 35° C. with stirring, to thereby prepare a milky lotion.
  • the present invention can be applied to design of a cosmetic or the like.

Abstract

A method for developing an excellent material for enhancing skin barrier function, and providing a cosmetic which is developed based on the method and has excellent ability to enhance skin barrier function is described. The method evaluates skin barrier function by the steps of 1) culturing normal human epidermal cells in wells having a semipermeable membrane with two sides, in presence and absence of a test substance; 2) adding a medium not containing metal ions to a first side of the semipermeable membrane in each well and a medium containing the metal ions to a second side of the semipermeable membrane in each well, provided that the cells are adhered to the first side of the semipermeable membrane; 3) culturing the cells; 4) measuring the concentration of the metal ions in each medium; and 5) calculating permeability of the metal ions in the epidermal cell layer based on the measured concentrations of the metal ions in each media. The test substance is effective for enhancing skin barrier function when the permeability is reduced in the medium in which the test substance is added compared to the permeability in the medium in which no test substance is added. The larger the level of reduced permeability, the higher the suitability of the test substance as a material for enhancing skin barrier function.

Description

    TECHNICAL FIELD
  • The present invention relates to a method of evaluating skin barrier function, a method of screening material for enhancing skin barrier function using the evaluating method, the material for enhancing skin barrier function, and a cosmetic containing the material for enhancing skin barrier function.
  • BACKGROUND ART
  • At present days, patients who suffer from skin diseases due to skin barrier dysfunction, such as a high incidence of atopic dermatitis, have increased rapidly. This is considered to be caused by an excessive increase in stress (see, for example, Patent Documents 1, 2, 3, and 4). In fact, there is a high incidence of the skin barrier dysfunction, so it is required to develop means for preventing a disease in an early stage from becoming severe or means for ameliorating an actual symptom.
  • However, in many cases, expression of the skin barrier dysfunction described above is liable to be recognized after developments of severe symptoms such as an occurrence of skin roughness and a rapid increase in amount of transepidermal water loss. Accordingly, it can be said that the development of means for detecting such skin barrier dysfunction in an early stage has been desired.
  • There are some proposals on animal models for skin barrier dysfunction (see, for example, Patent Documents 5 and 6), but in all the proposals, animals must be used and much time and efforts are required. Further, there is a room for doubt about its reproducibility. Moreover, in such screening using animal models, the number of test samples to be evaluated is limited.
  • There has not been known at all a method of evaluating skin barrier function using culture cells.
  • Meanwhile, there has been known that a calcium ion is involved in differentiation/maturation of epidermal/horny layer cells, and that presence of an appropriate amount of the calcium ion gives order to differentiation/maturation of epidermal/horny layer cells. Also, there has been known that an appropriate concentration gradient of the calcium ion from a lower layer of an epidermis toward an upper layer thereof provides a function of constructing a sufficient barrier structure. However, there has been also known that the excessive calcium ion impairs the skin barrier function (see, for example, Non-patent Documents 1, 2, and 3). Moreover, a technology for adjusting the concentration of a metal ion such as a calcium ion in the skin has not been known at all.
  • [Patent Citation 1] JP 2002-291909 A
  • [Patent Citation 2] JP 2000-159666 A
  • [Patent Citation 3] JP 2000-035425 A
  • [Patent Citation 4] JP 10-279505 A
  • [Patent Citation 5] JP 2001-321016 A
  • [Patent Citation 6] WO 2003/053466
  • [Non Patent Citation 1] Hwang J. et al, J Biol Chem., (2007), in print
  • [Non Patent Citation 2] Ahn B K. et al, Arch Dermatol Res., 2007; 299(2): 53-7
  • [Non Patent Citation 3] Yuki T. et al, Experimental Dermatology, 2007; 16(4), 324-330
  • DISCLOSURE OF INVENTION
  • The present invention has been made under the above-mentioned circumstances, and it is an object of the present invention to provide a technology for developing an excellent material for enhancing skin barrier function, and to develop and provide a cosmetic having excellent ability to enhance the skin barrier function based on the technology.
  • In view of the above-mentioned circumstances, the inventors of the present invention found that a material for enhancing skin barrier function that is excellent as a cosmetic material can be obtained by screening the material using movement of metal ions as an index, in particular, calcium ions that affect differentiation of a horny layer cell, from dermis or tissue equivalent for the dermis to horny layer cell, and thus completed the present invention. That is, the present invention is as follows.
    • (1) A method of evaluating skin barrier function, comprising:
  • using permeability of metal ions through an epidermal cell layer as an index, and evaluating that the higher the permeability of the metal ions, the lower the skin barrier function.
    • (2) The method of evaluating skin barrier function according to (1), wherein a type of the metal ions is calcium ion and/or magnesium ion.
    • (3) A method of screening material for enhancing skin barrier function, comprising:
  • 1) culturing normal human epidermal cells in wells with a semipermeable membrane bottom, in presence and absence of a test substance;
  • 2) adding a medium not containing metal ions to be measured to the above of cells in each well and a medium containing the metal ions to be measured to the below of the cells in each well, provided that the below is a side where the cells are adhered to the semipermeable membrane, and the above is an opposite side thereto, and culturing the cells;
  • 3) measuring a concentration of the metal ions in each medium; and
  • 4) calculating permeability of the metal ions in an epidermal cell layer based on the measured concentrations of the media, discriminating that the test substance is effective as the material for enhancing skin barrier function in a case where the permeability is reduced in the medium in which the test substance is added compared to the permeability in the medium in which no test substance is added, and evaluating that the larger the level of reduced permeability, the higher the suitability of the test substance as the material for enhancing skin barrier function.
    • (4) The method of screening material for enhancing skin barrier function according to (3), wherein a type of the metal ions is calcium ion and/or magnesium ion.
    • (5) The method of screening material for enhancing skin barrier function according to (4), wherein the type of the metal ion is calcium ion.
    • (6) A material for enhancing skin barrier function, which is judged to be effective by the method of screening material for enhancing skin barrier function according to any one of (3) to (5).
    • (7) An adjuster for calcium ion in epidermis, comprising the material for enhancing skin barrier function according to (6).
    • (8) A cosmetic comprising the material for enhancing skin barrier function according to (6).
    Advantageous Effects
  • According to the present invention, it is possible to provide a technology for developing an excellent material for enhancing skin barrier function, and to develop and provide a cosmetic having excellent ability to enhance the skin barrier function based on the technology.
  • BRIEF DESCRIPTION OF DRAWINGS
  • [FIG. 1] Graphs each showing a relationship between an added metal ion concentration and a permeability coefficient obtained in Example
  • [FIG. 2] Graphs each showing a relationship between TER and the permeability coefficient obtained in Example 1.
  • [FIG. 3] Graphs each showing a comparison result of media obtained in Example 2.
  • [FIG. 4] A graph showing results according to Example 3.
  • [FIG. 5] Graphs each showing results according to Examples 4 to 7.
  • [FIG. 6] A graph showing results according to Examples 8, 10, and 11.
  • [FIG. 7] A graph showing results according to Example 9.
  • [FIG. 8] A graph showing the results of Examples 12 and 13.
  • BEST MODE FOR CARRYING OUT THE INVENTION
  • A method of evaluating skin barrier function is characterized by using permeability of metal ions through an epidermal cell layer as an index. The method uses permeability from a basal layer to a horny layer as the index. Note that the term “permeability” as used herein refers to both an ability of a substance to enter into and exit from cells and an ability of a substance to pass through cells. It is evaluated that the higher the permeability of the metal ions, the lower the skin barrier function. The evaluating method, for example, can be performed as follows:
  • 1) culturing normal human epidermal keratinocytes in wells with a semipermeable membrane bottom; 2) adding a medium not containing metal ions to be measured to the apical side of keratinocytes in each well and a medium containing the metal ions to be measured to the basolateral side of the keratinocytes in each well, provided that the basolateral side is a side where the keratinocytes are adhered to the semipermeable membrane, and the apical side is an opposite side thereto, and culturing the keratinocytes under metal ion loaded condition; 3) measuring a concentration of the metal ions in each medium; and 4) calculating permeability of the metal ions in an epidermal cell layer based on the measured concentrations of the media to evaluate the skin barrier function.
  • The epidermal cells may be epidermal cells of any sites, and examples thereof include a foreskin of a newborn baby and a breast of an adult woman. The epidermal cells may be commercially available epidermal cells. Examples of the commercially available epidermal cells include normal human newborn foreskin epidermal keratinocytes (NHEK) (manufactured by Kurabo Industries Ltd.). The epidermis is composed of a basal layer, a prickle cell layer, a granule layer, and a horny layer. In the evaluating method of the present invention, cells of all of the layers may be used, but basal layer cells are preferably used. The cell culture conditions or the like may be general conditions. The culture time under a metal ion loaded condition is generally about one to three hours. The concentration of loaded metal ions is generally about 5 to 10 mM.
  • Such evaluation may be performed in vitro for, e.g., three-dimensionally cultured epidermal cells as described above or for living experimental animals. Meanwhile, the evaluating method of the present invention may be used to uniformize a barrier function by measuring the value of the movement of metal ions for each prepared culture product to determine homogeneity.
  • As more developed application, the evaluating method of the present invention can be used for evaluating whether a test substance acts for enhancing or inhibiting skin barrier function in a formation of an epidermal cell membrane by comparing the cases of culture of normal human epidermal cells in presence and absence of the test substance.
  • From the viewpoint of improvement (strengthening) of skin barrier function, the evaluating method of the present invention can be applied to screening of a component for improving skin barrier function. For example, the screening can be performed by: defining a value calculated by the following expression: (1−metal ion permeation ratio in the presence of a test substance/metal ion permeation ration in the absence of a test substance)×100; and evaluating that the larger the value, the higher the ability to improve skin barrier function. The method can discriminate that the higher the ability to inhibit permeability of calcium or the like, the higher the ability to improve the skin barrier function. Such inhibition of permeation can control the concentration of ion such as calcium in the epidermis to correct the concentration gradient to an appropriate value. This promotes appropriate differentiation/maturation of epidermal/horny layer cells, resulting in improvement of barrier function of the horny layer. The screening described above may be performed by using normal epidermal cells derived from human or normal epidermal cells derived from an animal other than human. In addition, epidermal cells having specific properties are created by transforming the cells by masking a part of genes with complementary genes or introducing another gene into the cells using a vector or the like, and the epidermal cells may be used for the screening as in the above.
  • The metal ions to be used for the evaluation are not particularly limited as long as they are unevenly distributed in a living body, and are particularly preferably alkaline earth metals, and of those, a calcium and/or magnesium ion is preferred. Most preferred is a calcium ion. This is because the calcium ion acts as a cell differentiation factor in epidermal cells, and is a metal ion to be controlled in a condition that skin barrier function is normal, and excess permeation of the calcium ion in an epidermal cell layer is an absolute evidence of the skin barrier dysfunction. The efflux of the calcium ion from the epidermis,that is, excess passage of the calcium ion may prevent the maturation of horny layer cells and the formation of strong skin barrier function. A material to prevent such phenomenon can improve the barrier function in the epidermis and promote the maturation of healthy horny layer cells in a horny cell layer, resulting in improvement of the skin barrier function.
  • Means for qualitatively labeling such a metal ion has been known, and the labeling means may be used to clarify distribution of a metal ion such as a calcium ion in a living body. In the evaluating method of the present invention, such means maybe employed. Examples of a preferable label for the calcium ion include a dye such as Arsenazo III or a salt thereof. Examples of a preferable label for a magnesium ion include Xylidyl blue I. The concentration of the label is 0.001 mM to 1,000 mM. An area where the label is localized is considered as an area where a metal ion such as calcium is also localized. In addition, an area where the concentration of the label is higher is considered as an area where the concentration of the metal ion such as a calcium ion is higher.
  • A material for enhancing skin barrier function of the present invention is a material for enhancing skin barrier function, which is judged to be effective by a method of screening material for enhancing the skin barrier function. The material is preferably includes a component that significantly inhibits the transference of calcium from the dermis, tissue equivalent for dermis, or deep part of the epidermis to the horny layer or tissue equivalent for horny layer in the presence of a test substance compared with the case in the absence of the test substance. Such an action is dose-dependent, and the material is preferably blended into a cosmetic in an amount within a range to give dose dependency. The dose for the action varies depending on type of materials, and is for example, 0.01 mM to 50 mM, and in terms of an animal or plant extract, 0.001 to 10% (final concentration in use). If the dose is within the range, the material can act as an adjuster for a calcium ion in the horny layer and improve the barrier function in the horny layer.
  • Specific preferred examples of the material for enhancing skin barrier function, which serves as an adjuster for a calcium ion, include: solvent-removed products or fractionated products of extracts obtained from peels of plants of the genus Citrus in the family Rutaceae such as orange, Citrus tachibana, and Citrus aurantium with a polar solvent, preferably an aqueous solution of 30 to 70% ethanol; solvent-removed products or fractionated products of extracts obtained from seeds of plants of the genus Pimpinella in the family Apiaceae such as Japanese honewort and fennel with a polar solvent, preferably an aqueous solution of 30 to 70% ethanol; extract, preferably, solvent-removed products or fractionated products of extracts obtained from flowers or flower buds of plants of the genus Bellis in the family Compositae such as Bellis perennis with a polar solvent, preferably an aqueous solution of 30 to 70% ethanol; royal jerry or a protein thereof, or a hydrolysate thereof; extract, preferably, solvent-removed products or fractionated products of extracts obtained from barks of plants of the genus Fagus in the family Fagaceae such as Fagus crenata Blume, Fagus grandifolia Ehrh, Fagus japonica Maxim, and Fagus sylvatica, preferably Fagus sylvatica with a polar solvent, preferably an aqueous solution of 30 to 70% ethanol; extract, preferably, solvent-removed products or fractionated products of extracts obtained from terrestial parts of plants of the genus Chamerion in the family Onagraceae such as Epilobium angustifolium with a polar solvent, preferably an aqueous solution of 30 to 70% ethanol; extract, preferably, solvent-removed products or fractionated products of extracts obtained from flowers or flower buds of Capparis spinosa of the family Capparidaceae with a polar solvent, preferably an aqueous solution of 30 to 70% ethanol; extracts obtained from bodies, preferably rhizome of plants of the genus Coptis in the family Ranunculaceae such as Coptis japonica MAKINO var. japonica SATAKE, Coptis japonica MAKING var. dissecta NAKAI, and Coptis japonica (Makino) Thunb. var. major (Miq.) Satake with an aqueous solution of 30 to 70% ethanol, or optionally solvent-removed products or optionally fractionated products of the extracts; red alga extracts obtained by extracting red algae such as Palmaria palmate with water, adjusting molecular weights by ultrafiltration, if necessary, and removing the solvents; extract, preferably, solvent-removed products or fractionated products of extracts obtained from an echinoderm of the order Asterina in the class Asteroidea with a polar solvent, preferably an aqueous solution of 30 to 70% ethanol; and extract, preferably, solvent-removed products or fractionated products of extracts obtained from dried products of terrestial parts of plants of the genus Houttuynia in the family Saururaceae such as Houttuynia cordata with a polar solvent, preferably an aqueous solution of 30 to 70% ethanol.
  • Such a component is blended into a cosmetic in an amount of 0.01 to 10% by mass, more preferably 0.05 to 1% by mass based on the total amount of the cosmetic. The reason is as follows: if the amount is too small, the above-mentioned effects cannot be obtained in some cases, while if the amount is too large, the amount of the component delivered to the epidermis may reach a plateau, and freedom of the prescription may be unnecessarily impaired.
  • The cosmetic of the present invention is characterized by containing a strengthening material of the skin barrier function. The cosmetic of the present invention can contain optional ingredients used commonly in a cosmetic as well as those ingredients. Preferred examples of such an optional component include: oils/waxes such as macadamia nut oil, avocado oil, corn oil, olive oil, rapeseed oil, sesame oil, castor oil, safflower oil, cottonseed oil, jojoba oil, coconut oil, palm oil, liquid lanolin, cured coconut oil, cured oil, Japan wax, cured castor oil, beeswax, candelilla wax, carnauba wax, ibota wax, lanolin, reduced lanolin, hard lanolin, and jojoba wax; hydrocarbons such as liquid paraffin, squalane, pristane, ozokerite, paraffin, ceresin, vaseline, and microcrystalline wax; higher fatty acids such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, and undecylenic acid; higher alcohols such as cetyl alcohol, stearyl alcohol, isostearyl alcohol, behenyl alcohol, octyldodecanol, myristyl alcohol, and cetostearyl alcohol; oil solutions of synthetic ester such as cetyl isooctanoate, isopropyl myristate, hexyldecyl isostearate, diisopropyl adipate, di-2-ethylhexyl sebacate, cetyl lactate, diisostearyl malate, ethylene glycol di-2-ethyl hexanoate, neopentylglycol dicaprate, di-2-heptyl undecanoic acid glyceride, tri-2-ethylhexanoic acid glyceride, trimethylolpropane tri-2-ethylhexanoate, trimethylolpropane triisostearate, and pentaerythritol tetra-2-ethylhexanoate; chain polysiloxanes such as dimethylpolysiloxane, methylphenylpolysiloxane, and diphenylpolysiloxane; ring polyoxanes such as octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, and dodecamethylcyclohexanesiloxane; modified polysiloxanes including amino-modified polysiloxane, polyether-modified polysiloxane, alkyl-modified polysiloxane, and fluorine-modified polysiloxane; anionic surfactants such as fatty acid soaps (such as sodium laurate and sodium palmitate), potassium lauryl sulfate, and triethanolamine alkylsulfate ether; cationic surfactants such as trimethyl ammonium stearyl chloride, benzalkonium chloride, and laurylamine oxide; amphoteric surfactants such as imidazoline-based amphoteric surfactants (such as a 2-cocoyl-2-imidazolinium hydroxide-1-carboxyethyloxy-2-sodium salt), betaine-based surfactants (such as alkyl betaine, amide betaine, and sulfo betaine), and acylmethyl taurine; nonionic surfactants such as sorbitan fatty acid esters (such as sorbitan monostearate and sorbitan sesquioleate), glycerol fatty acid esters (such as glycerin monostearate), propyleneglycol fatty acid esters (such as propyleneglycol monostearate), cured castor oil derivatives, glycerol alkylether, POE sorbitan fatty acid esters (such as POE sorbitan monooleate and polyoxyethylene sorbitan monostearate), POE sorbitol fatty acid esters (such as POE-sorbitol monolaurate), POE glycerol fatty acid esters (such as POE-glycerol monoisostearate), POE fatty acid esters (such as polyethyleneglycol monooleate and POE distearate), POE alkyl ethers (such as POE2-octyldodecyl ether), POE alkylphenyl ethers (such as POE nonylphenylether), pluronic types, POE/POP alkyl ethers (such as POE/POP2-decyltetradecyl ether), tetronic types, POE castor oil/cured castor oil derivatives (such as POE castor oil and POE cured castor oil), sucrose fatty acid ester, and alkyl glucoside; polyols such as polyethylene glycol, glycerol, 1,3-butylene glycol, erythritol, sorbitol, xylitol, maltitol, propylene glycol, dipropylene glycol, diglycerin, isoprene glycol, 1,2-pentanediol, 2,4-hexylene glycol, 1,2-hexanediol, and 1,2-octanediol; moisturizing components such as sodium pyrrolidone carboxylate, lactate, and sodium lactate; fine particles such as mica, talc, kaolin, synthetic mica, calcium carbonate, magnesium carbonate, silicic anhydride (silica), aluminum oxide, and barium sulfate, whose surfaces may be treated; inorganic pigments such as red iron oxide, yellow iron oxide, black iron oxide, cobalt oxide, ultramarine blue, iron blue, titanium oxide, and zinc oxide, whose surfaces may be treated; pearlescent pigments such as mica titanium, fish scale foil, and bismuth oxychloride, whose surfaces maybe treated; organic dyes such as Red No. 202, Red No. 228, Red No. 226, Yellow No. 4, Blue No. 404, Yellow No. 5, Red No. 505, Red No. 230, Red No. 223, Orange No. 201, Red No. 213, Yellow No. 204, Yellow No. 203, Blue No. 1, Green No. 201, Purple No. 201, and Red No. 204, which may be laked; organic fine particles such as polyethylene powder, polymethyl methacrylate powder, nylon powder, and organopolysiloxane elastomer; ultraviolet absorbents such as a p-aminobenzoate-based ultraviolet absorbent; an anthranilate-based ultraviolet absorbent; a salicylate-based ultraviolet absorbent; a cinnamate-based ultraviolet absorbent; a benzophenone-based ultraviolet absorbent; a sugar-based ultraviolet absorbent; 2-(2′-hydroxy-5′-t-octylphenyl) benzotriazole, and 4-methoxy-4′-t-butyldibenzoylmethane; lower alcohols such as ethanol and isopropanol; vitamins such as vitamin A or derivatives thereof, vitamin B types such as vitamin B6 hydrochloride, vitamin B6 tripalmitate, vitamin B6 dioctanoate, vitamin B2 or derivatives thereof, vitamin B12, and vitamin B15 or derivatives thereof, vitamin E types such as α-tocopherol, β-tocopherol, γ-tocopherol, and vitamin E acetate, vitamin D types, vitamin H, pantothenic acid, pantethine, and pyrroloquinoline quinone; and antibacterial agents such as phenoxyethanol.
  • A cosmetic of the present invention can be produced by processing a material for enhancing skin barrier function, which is an essential component and serves as an adjuster for a calcium ion in the horny layer, together with the above-mentioned optional components in accordance with a conventional method. It is particularly preferable to accurately deliver the material for enhancing skin barrier function to the epidermis in an appropriate manner. Therefore, the material may be incorporated into a delivery compartment such as liposome, double-membrane vesicle, or fat globule such delivery compartment that carries a material for enhancing skin barrier function may be incorporated into a cosmetic. The cosmetic particularly preferably contains such a delivery compartment. Meanwhile, a formulation of the cosmetic is not particularly limited as long as it is generally known, and preferable examples of the cosmetic include lotion cosmetics, milky lotion cosmetics, cream cosmetics, essence cosmetics, pack cosmetics, under makeup cosmetics, and foundations, and of those, particularly preferable are lotion cosmetics, milky lotion cosmetics, cream cosmetics, essence cosmetics, pack cosmetics, etc.
  • Examples
  • Hereinafter, the present invention will be described in more detail with reference to examples, but it will be obvious that the present invention is not limited to the examples.
  • Example 1
  • An ion permeability test using normal human epidermal cells was performed based on a method of evaluating skin barrier function of the present invention.
  • 1) Cell Inoculation and Ion Permeability Experiment
  • Frozen normal human epidermal keratinocytes (NHEK) (manufactured by Kurabo Industries Ltd.) were thawed and cultured in a 0.15 mM Ca-containing culture medium (Humedia-KG2; manufactured by Kurabo Industries Ltd.) at 37° C. in 50% carbon dioxide atmosphere. A Transwell (registered trademark) manufactured by Corning Incorporated (diameter 12 mm, polyethylene terephthalate, 0.4 μm pore) was placed on a Millicell (registered trademark) tissue culture plate (manufactured by Millipore), and the above-mentioned culture medium was added in amounts of 1.5 ml to the lower layer and 0.5 ml to the upper layer. Then, the normal human epidermal keratinocytes (NHEK) were inoculated at 1×105/cm2 and cultured for additional 72 hours. After the cells were confirmed to be confluent, the culture medium was exchanged for a 1.45-mM Ca-containing Humedia KG2 medium, and the cells were cultured for additional 96 hours. When TERs (transepithelial electrical resistance) reach the peak (350 to 450 Ω·cm2), and the prepared solutions described in Table 1 were each added to the basolateral side in an amount of 1.5 ml, and the prepared solutions described in Table 1 were each added to the apical side in an amount of 0.5 ml. Static cultures were each performed at 37° C. in 5% carbon dioxide atmosphere for two hours, and the solutions of the apical and basolateral sides were each recovered.
  • TABLE 1
    apical soln. basal soln. (f.c.)
    (f.c.) (a) (b) (c) (d) (e) (f)
    Solutions for Ca2+ permeation experiments
    MgCl2  1 mM 1 mM
    glucose
     10 mM 10 mM
    HEPES  10 mM (pH 7.4) 10 mM (pH 7.4)
    Mannitol 280 mM 130 mM 220 mM 250 mM 265 mM 274 mM
    CaCl2 100 mM  50 mM  20 mM  10 mM  5 mM  2 mM
    Solutions for Mg2+ permeation experiments
    CaCl
    2  1 mM 1 mM
    glucose
     10 mM 10 mM
    HEPES  10 mM (pH 7.4) 10 mM (pH 7.4)
    Mannitol 280 mM 130 mM 220 mM 250 mM 265 mM 274 mM
    MgCl2 100 mM  50 mM  20 mM  10 mM  5 mM  2 mM
  • 2) Ion Permeability Coefficient Calculation Formula
  • The recovered samples were quantified with quantification reagents {Ca-Arsenazo-III, Mg-Xylidyl blue I (both are manufactured by Fluka)}. The quantification flow is shown below. The net flux (mass transfer per unit time and unit area) was calculated from the quantification results, and Ca and Mg ion permeability coefficients were calculated by the following formula.
  • P ( n mol / mM / h / cm 2 ) = NetFlux ( n mol / h / cm 2 ) C basolateral ( mM ) Formula 1
  • 3) Ca Quantification
  • a) 7.76 mg of Arsenazo III was dissolved in 100 μl of 1N NaOH, and the volume of the solution was adjusted to 50 ml with the apical solution for Ca prepared in Table 1 (Ca quantification solution).
  • b) An aqueous solution of 1M CaCl2 was diluted with the apical solution to prepare 0.01 to 1 mM Ca-standard solutions, and the Ca-standard solutions and Ca quantification solution were each added to a 96-well plate in an amount of 50 μl/well to measure ODs (600), followed by creation of a calibration curve.
  • c) In order to quantify Ca in a sample, the Ca quantification solution and the sample were each added to the plate in an amount of 50 μl/well to measure ODs (600). If the resultant value was above the range of the calibration curve, the sample was diluted with the apical solution.
  • 4) Mg Quantification
  • a) 5.13 mg of Xylidyl blue I was dissolved in 200 μl of 1N NaOH, and the volume of the solution was adjusted to 50 ml with a borate buffer (prepared by mixing 40 ml of 0.2 mol/1 NaOH, 0.2 mol/1 KCl, and 50 ml of a H3BO3 mix solution (15 g of KCl and 12.5 g of H3BO3 were dissolved into distilled water to be adjusted to 1 l), pH 10). (Mg quantification solution)
  • b) An aqueous solution of 1M MgCl2 was diluted with the apical solution to prepare 0.01 to 1 mM Mg-standard solutions, and the Mg-standard solutions (15 μl/well) and the Mg quantification solution (100 μl/well) were added to a 96-well plate to measure ODs (520), followed by creation of a calibration curve.
  • c) In order to quantify Mg in a sample, the Mg quantification solution (15 μl/well) and the sample (100 μl/well) were added to the plate to measure ODs (520). If the resultant value was above the range of the calibration curve, the sample was diluted with the apical solution before measurement.
  • 5) Correlation Between TER and Permeability Coefficient
  • Frozen normal human epidermal keratinocytes (NHEK) (manufactured by Kurabo Industries Ltd.) were thawed and cultured in a 0.15 mM Ca-containing culture medium (Humedia-KG2; manufactured by Kurabo Industries Ltd.) at 37° C. in 50% carbon dioxide atmosphere. A Transwell (registered trademark) manufactured by Corning Incorporated (diameter 12 mm, polyethylene terephthalate, 0.4 μm pore) was placed on a Millicell (registered trademark) tissue culture plate (manufactured by Millipore), and the above-mentioned culture medium was added in amounts of 1.5 ml to the lower layer and 0.5 ml to the upper layer. Then, the normal human epidermal keratinocytes (NHEK) were inoculated at 1×105/cm2 and cultured for additional 72 hours. After the cells were confirmed to be confluent, the culture medium was exchanged for a 1.45 mM Ca-containing Humedia KG2 medium, and the cells were cultured for additional 96 hours. TERs were measured, and the prepared solution described in Table 1-1 (e) or Table 1-2 (e) was added to the basolateral side in an amount of 1.5 ml, and the prepared solution described in Table 1-1 or Table 1-2 was each added to the apical side in an amount of 0.5 ml. Static cultures were each performed at 37° C. in 5% carbon dioxide atmosphere for two hours, and the solutions of the apical and basolateral sides were each recovered, followed by measurement of ion permeability coefficients. After the measurement, the medium was exchanged for a 1.45 mM Ca-containing Humedia KG2 medium, and one and two days later, TERs and ion permeability coefficients were measured by the same procedures as above.
  • 6) Results
  • Relationships between added metal ion concentrations and permeability coefficients are shown in FIG. 1. The results revealed that the permeability coefficients were significantly high at concentrations of 5 mM or less, so it was found that, if metal ion loaded concentrations are set within the range, the influences can be evaluated more clearly. In addition, TERs were found to be negatively correlated with permeability coefficients, and the fact supports that the permeability coefficients are values correlated with skin barrier function. The results are shown in FIG. 2.
  • Example 2
  • In the same way as in Example 1, calcium was selected as a metal ion to be added to compare calcium permeability coefficients and magnesium permeability coefficients in a low-calcium medium cultured cells (shown as Ca− in FIG. 3) (0.15 mM) and in a high-calcium medium cultured cells (shown as Ca+ in FIG. 3) (1.45 mM). That is, frozen normal human epidermal keratinocytes (NHEK) (manufactured by Kurabo Industries Ltd.) were thawed and cultured in a 0.15 mM Ca-containing culture medium (Humedia-KG2; manufactured by Kurabo Industries Ltd.) at 37° C. in 50% carbon dioxide atmosphere. A Transwell (registered trademark) manufactured by Corning Incorporated (diameter 12 mm, polyethylene terephthalate, 0.4 μm pore) was placed on a Millicell (registered trademark) tissue culture plate (manufactured by Millipore), and the above-mentioned culture medium was added in amounts of 1.5 ml to the lower layer and 0.5 ml to the upper layer. Then, the normal human epidermal keratinocytes (NHEK) were inoculated at 1×105/cm2 and cultured for additional 72 hours. After the cells were confirmed to be confluent, in the case of the low-calcium medium, Humedia-KG2 medium was not exchanged, while in the case of the high-calcium medium, the culture medium was exchanged for a 1.45 mM Ca-containing Humedia KG2 medium, and the cells were further cultured. One day later, TERs were measured, and the prepared solution described in Table 1-1 (e) or Table 1-2 (e) was added to the basolateral side in an amount of 1.5 ml, and the prepared solution described in Table 1-1 or Table 1-2 was each added to the apical side in an amount of 0.5 ml. Static cultures were each performed at 37° C. in 5% carbon dioxide atmosphere for two hours, and the solutions of the apical and basolateral sides were each recovered, followed by measurement of ion permeability coefficients. After the measurement, the medium was exchanged for Humedia-KG2 medium or a 1.45 mM Ca-containing Humedia KG2 medium, and one to five days later, TERs and ion permeability coefficients were measured by the same procedures as above. The results are shown in FIG. 3. The results revealed that, in the keratinocytes grown in the high-calcium medium, with progress in the formation of tight junctions, the TERs increase and ion permeability coefficients decrease. This supports that calcium acts as an index of skin barrier function and affects the formation of cell membranes, that is, affects the skin barrier itself, and control of its permeability is important for considering the skin barrier function.
  • Example 3
  • TERs and metal ion permeability coefficients in the case where claudin-1, one of tight junction proteins serving as adhesion factors for epidermal cells, was suppressed with siRNA were measured in accordance with the method of Example 1. That is, frozen normal human epidermal keratinocytes (NHEK) (manufactured by Kurabo Industries Ltd.) were thawed and cultured in a 0.15 mM Ca-containing culture medium (Humedia-KG2; manufactured by Kurabo Industries Ltd.) at 37° C. in 50% carbon dioxide atmosphere. Thereafter, siRNA was transfected into the cultured cells. A Transwell (registered trademark) manufactured by Corning Incorporated (diameter 12 mm, polyethylene terephthalate, 0.4 μm pore) was placed on a Millicell (registered trademark) tissue culture plate (manufactured by Millipore), and the above-mentioned culture medium was added in amounts of 1.5 ml to the lower layer and 0.5 ml to the upper layer. Then, the human epidermal keratinocytes transfected with siRNA were inoculated at 2.5×105/cm2 and cultured for additional 24 hours. After the cells were confirmed to be confluent, the culture medium was exchanged for a 1.45 mM Ca-containing Humedia KG2 medium, and the cells were cultured for 48 hours. TERs were measured, and the prepared solution described in Table 1-1 (e) or Table 1-2 (e) was added to the basolateral side in an amount of 1.5 ml, and the prepared solution described in Table 1-1 or Table 1-2 was each added to the apical side in an amount of 0.5 ml. Static cultures were each performed at 37° C. in 5% carbon dioxide atmosphere for two hours, and the solutions of the apical and basolateral sides were each recovered, followed by measurement of ion permeability coefficients. The results are shown in FIG. 4. The results revealed that when claudin-1 is suppressed, the TERs decrease and the permeability coefficients of metal ions such as calcium and magnesium increase. This suggested that a tight junction protein such as claudin-1 affected permeation of the metal ions, thereby affecting the skin barrier function.
  • Example 4
  • 3 l of an aqueous solution of 50% ethanol was added to 500 g of pulverized seeds of a plant of the genus Pimpinella in the family Apiaceae, and the mixture was heated with stirring to perform reflux for three hours. After cooling to room temperature, insoluble matters were removed by filtration, and the filtrate was concentrated under reduced pressure. 1 l of water and 1 l of ethyl acetate were added to the residue to perform liquid-liquid extraction. The ethyl acetate layer was collected, washed with 500 ml of water twice, dried with anhydrous sodium sulfate, and concentrated under reduced pressure, and the solvent was removed, to thereby yield a Pimpinella extract 1. Cells obtained by three-dimensional culture by the procedure of Example 1-1) were cultured in the presence of 10-1% of the Pimpinella extract 1 at a calcium loaded concentration of 5 mM, and a calcium ion was stained by the procedure of Example 1-3) and an absorbance was measured. A test substance having a concentration of 0 was defined as a control, and a calcium ion permeation ratio was calculated. The results are shown in FIG. 5. The results revealed that Pimpinella extract 1 had ability to inhibit the transference of a calcium ion from the dermis/the deep part of the epidermis to the horny cell layer.
  • Example 5
  • To study inhibition of the transference of a calcium ion, the same procedure as in Example 4 was repeated except that L-carnitine (manufactured by Sigma) was used instead of the Pimpinella extract 1. The results are shown in FIG. 5. The results revealed that L-carnitine had ability to inhibit the transference of a calcium ion from the dermis/the deep part of the epidermis to the horny cell layer.
  • Example 6
  • 3 l of water was added to 500 g of a dried product of an echinoderm of the order Asterina in the class Asteroidea, and the mixture was heated with stirring to perform reflux for three hours. After cooling to room temperature, insoluble matters were removed by filtration, and the filtrate was concentrated under reduced pressure, to thereby yield an Asteroidea extract 1. To study inhibition of the transference of a calcium ion, the same procedure as in Example 4 was repeated except that the Asteroidea extract 1 was used instead of the Pimpinella extract 1. The results are shown in FIG. 5. The results revealed that the Asteroidea extract 1 had ability to inhibit the transference of calcium ion from the dermis/the deep part of the epidermis to the horny cell layer.
  • Example 7
  • To study inhibition of the transference of a calcium ion, the same procedure as in Example 4 was repeated except that hydrolyzed royal jelly protein (“Royal Biocyte PX”, manufactured by Katakura Chikkarin Co., Ltd.) was used instead of the Pimpinella extract 1. The results are shown in FIG. 5. The results revealed that the hydrolyzed royal jelly protein had ability to inhibit the transference of a calcium ion from the dermis/the deep part of the epidermis to the horny cell layer.
  • Example 8
  • The whole plant body of Palmaria palmate was dried, and 100 g of the dried product was weighed. 2 l of water was added to the product, and the mixture was gradually heated up to 60° C. The temperature was maintained for three hours, and the mixture was cooled to room temperature. After cooling, insoluble matters were removed by filtration, and the filtrate was freeze-dried, to thereby yield a Palmaria extract 1. To study inhibition of the transference of a calcium ion, the same procedure as in Example 4 was repeated except that the Palmaria extract 1 was used instead of the Pimpinella extract 1. The results are shown in FIG. 6. The results revealed that the Palmaria extract 1 had ability to inhibit the transference of a calcium ion from the dermis/the deep part of the epidermis to the horny cell layer.
  • Example 9
  • Frozen normal human epidermal keratinocytes (NHEK) (manufactured by Kurabo Industries Ltd.) were thawed and cultured in a 0.15 mM Ca-containing culture medium (Humedia-KG2; manufactured by Kurabo Industries Ltd.) at 37° C. in 50% carbon dioxide atmosphere. A Transwell manufactured by Corning Incorporated (diameter 12 mm, polyethylene terephthalate, 0.4 μm pore) was placed on a Millicell tissue culture plate (manufactured by Millipore), and the above-mentioned culture medium was added in amounts of 0.5 ml to the upper layer and 1.5 ml to the lower layer. Then, the normal human epidermal keratinocytes (NHEK) were inoculated at 1×105/cm2 and cultured for additional 72 hours. After the cells were confirmed to be confluent, the culture medium was exchanged for a 1.45 mM Ca-containing Humedia KG2 medium, and the cells were cultured for additional 96 hours. Thereafter, the medium was exchanged for a culture medium containing 10−4 v/v % α,ε-bis(γ-N-lauroylglutamyl)lysine (Pellicer L-30 (registered trademark) (hereinafter, referred to as Pellicer); manufactured by Asahi Kasei Corporation), and TERs were measured. The culture was further continued, and one, two, three, and four days later, TERs were measured. The graph shows changes with time in TER (transepitherial electrical resistance) values (Ω·cm2) after certain lengths of time with respect to TER values at the time of addition of the extract. The results are shown in FIG. 7. In addition, calcium ion permeability coefficients were measured in accordance with the procedure of Example 1, and it was found that the coefficients were inversely correlated with the changes in the TERs. The results revealed that addition of Pellicer inhibited the transference of a calcium ion and provided an increased resistance value compared with the control.
  • Example 10
  • To study inhibition of the transference of a calcium ion, the same procedure as in Example 4 was repeated except that ε,γ-glutamyl lysine was used instead of the Pimpinella extract 1. The results are shown in FIG. 6. The results revealed that ε,γ-glutamyl lysine had ability to inhibit the transference of the calcium ion from the dermis/the deep part of the epidermis to the horny cell layer.
  • Example 11
  • Effects of combination use of the Palmaria extract 1, α,ε-bis(γ-N-lauroylglutamyl)lysine (Pellicer), and ε,γ-glutamyl lysine were determined in the same as above. The results are shown in FIG. 6. The effects of combination use were confirmed.
  • Example 12
  • 3 l of an aqueous solution of 50% ethanol was added to 500 g of rhizome pieces of Coptis japonica of the genus Coptis in the family Ranunculaceae, and the mixture was heated with stirring to perform reflux for three hours. After cooling to room temperature, insoluble matters were removed by filtration, and the filtrate was concentrated under reduced pressure. 1 l of water and 1 l of ethyl acetate were added to the residue to perform liquid-liquid extraction. The ethyl acetate layer was collected, washed with 500 ml of water twice, dried with anhydrous sodium sulfate, and concentrated under reduced pressure, and the solvent was removed, to thereby yield a Coptis japonica extract 1.
  • Frozen normal human epidermal keratinocytes (NHEK) (manufactured by Kurabo Industries Ltd.) were thawed and cultured in a 0.15 mM Ca-containing culture medium (Humedia-KG2; manufactured by Kurabo Industries Ltd.) at 37° C. in 50% carbon dioxide atmosphere. A Transwell manufactured by Corning Incorporated (diameter 12 mm, polyethylene terephthalate, 0.4 μm pore) was placed on a Millicell tissue culture plate (manufactured by Millipore), and the above-mentioned culture medium was added in amounts of 0.5 ml to the upper layer and 1.5 ml to the lower layer. Then, the normal human epidermal keratinocytes (NHEK) were inoculated at 1×105/cm2 and cultured for additional 72 hours. After the cells were confirmed to be confluent, the culture medium was exchanged for a 1.45 mM Ca-containing Humedia KG2 medium, and the cells were cultured for additional 96 hours. Thereafter, the medium was exchanged for a culture medium containing 10−5 v/v % the Coptis japonica extract 1, and TERs were measured. The culture was further continued, and one, two, three, and four days later, TERs were measured. The graph shows changes with time in TER (transepitherial electrical resistance) values (Ω·cm2) after certain lengths of time with respect to TER values at the time of addition of the extract. The results are shown in FIG. 8. In addition, calcium ion permeability coefficients were measured in accordance with the procedure of Example 1, and it was found that the coefficients were inversely correlated with the changes in the TERs. The results revealed that addition of the Coptis japonica extract 1 inhibited the transference of the calcium ion and provided an increased resistance value compared with the control.
  • Example 13
  • The same procedure as in Example 12 was repeated except that a dried product of the peel of Citrus aurantium of the genus Citrus in the family Rutaceae was used instead of the rhizome of Coptis japonica, to thereby yield a Citrus aurantium peel extract 1. The extract was evaluated by measuring changes in resistance values caused by inhibition of the transference of the calcium ion in the same way as in Example 12. The results are shown in FIG. 8. The results revealed that the Citrus aurantium peel extract 1 had excellent ability to inhibit calcium.
  • Example 14
  • According to the following prescriptions, a cosmetic of the present invention was produced. Specifically, according to the following prescriptions, cosmetic of the present invention was prepared as milky lotions. That is, the components shown in (A) were mixed and heated to 80° C. On the other hand, the components shown in (B) were heated to 80° C. The mixture (B) was added to the mixture (A), and the whole was emulsified by stirring and neutralized by adding the components shown in (C), followed by cooling to 35° C. with stirring, to thereby prepare a milky lotion.
  • TABLE 2
    Components % by mass
    (A)
    Behenyl alcohol 0.5
    Cetyl isooctanate 2.0
    Squalane 8.0
    Dimethicone 2.0
    Sorbitan sesquistearate 1.5
    PEG-45 stearate 1.0
    Cetyl stearate 0.5
    Behenic acid 0.5
    (B)
    1,3-Butanediol 5.0
    Glycerol 5.0
    1,2-Octanediol 1.0
    Pure water 50.0
    Components described in Table 3 0.5
    Dipotassium glycyrrhizinate 0.1
    (C)
    Pure water 21.8
    Potassium hydroxide 0.6
    Total 100
  • TABLE 3
    Milky lotions Components
    Milky lotion
    1 Pimpinella extract 1
    Milky lotion 2 Asteroidea extract 1
    Milky lotion 3 L-Carnitine
    Milky lotion
    4 Royal jelly hydrolysate
    Milky lotion 5 Pellicer
    Milky lotion
    6 Palmaria extract 1
    Milky lotion 7 ε, γ-Glutamyl lysine
    Milky lotion 8 Coptis japonica extract 1
    Milky lotion 9 Citrus aurantium peel extract 1
  • INDUSTRIAL APPLICABILITY
  • The present invention can be applied to design of a cosmetic or the like.

Claims (14)

1. A method of evaluating skin barrier function using permeability of metal ions through an epidermal cell layer as an index, comprising:
determining permeability of metal ions through an epidermal cell layer, and
evaluating the permeability of the metal ions, wherein the higher the permeability of the metal ions, the lower the skin barrier function.
2. The method of evaluating skin barrier function according to claim 1, wherein the metal ions are calcium ions and/or magnesium ions.
3. A method of screening material for enhancing skin barrier function, comprising:
1) culturing normal human epidermal cells in wells comprising a semipermeable membrane with two sides, in presence and absence of a test substance;
2) adding a medium not containing metal ions to a first side of the semipermeable membrane in each well and a medium containing the metal ions to a second side of the semipermeable membrane in each well, provided that the cells are adhered to the first side of the semipermeable membrane, and the second side is opposite thereto;
3) culturing the cells;
4) measuring a concentration of the metal ions in each medium; and
5) calculating permeability of the metal ions in the epidermal cell layer based on the measured concentrations of the metal ions in each media, wherein the test substance is effective for enhancing skin barrier function when the permeability is reduced in the medium in which the test substance is added compared to the permeability in the medium in which no test substance is added, and evaluating that the larger the level of reduced permeability, the higher the suitability of the test substance as the material for enhancing skin barrier function.
4. The method of screening material for enhancing skin barrier function according to claim 3, wherein the metal ions are calcium ions and/or magnesium ions.
5. The method of screening material for enhancing skin barrier function according to claim 4, wherein the metal ion is calcium ion.
6. A material for enhancing skin barrier function, which is judged to be effective by the method according to claim 3.
7. An adjuster for calcium ion in epidermis, comprising the material for enhancing skin barrier function according to claim 6.
8. A cosmetic comprising the material for enhancing skin barrier function according to claim 6.
9. A material for enhancing skin barrier function, which is judged to be effective by the method according to claim 4.
10. An adjuster for calcium ion in epidermis, comprising the material for enhancing skin barrier function according to claim 9.
11. A cosmetic comprising the material for enhancing skin barrier function according to claim 9.
12. A material for enhancing skin barrier function, which is judged to be effective by the method according to claim 5.
13. An adjuster for calcium ion in epidermis, comprising the material for enhancing skin barrier function according to claim 12.
14. A cosmetic comprising the material for enhancing skin barrier function according to claim 12.
US12/516,483 2006-12-08 2007-12-07 Method of evaluating skin barrier function, method of screening material for enhancing skin barrier function using the evaluating method, the material for enhancing skin barrier function, and cosmetic containing the material for enhancing skin barrier function Abandoned US20100068309A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2006331294 2006-12-08
JP2006-331294 2006-12-08
JP2007-133776 2007-05-21
JP2007133776 2007-05-21
PCT/JP2007/074070 WO2008072717A1 (en) 2006-12-08 2007-12-07 Method of evaluating skin barrier function, method of screening material for enhancing skin barrier function using the evaluating method, the material for enhancing skin barrier function, and cosmetic containing the material for enhancing skin barrier function

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/074070 A-371-Of-International WO2008072717A1 (en) 2006-12-08 2007-12-07 Method of evaluating skin barrier function, method of screening material for enhancing skin barrier function using the evaluating method, the material for enhancing skin barrier function, and cosmetic containing the material for enhancing skin barrier function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/476,868 Division US8535904B2 (en) 2006-12-08 2012-05-21 Method of enhancing skin barrier function

Publications (1)

Publication Number Publication Date
US20100068309A1 true US20100068309A1 (en) 2010-03-18

Family

ID=39145239

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/516,483 Abandoned US20100068309A1 (en) 2006-12-08 2007-12-07 Method of evaluating skin barrier function, method of screening material for enhancing skin barrier function using the evaluating method, the material for enhancing skin barrier function, and cosmetic containing the material for enhancing skin barrier function
US13/476,868 Expired - Fee Related US8535904B2 (en) 2006-12-08 2012-05-21 Method of enhancing skin barrier function

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/476,868 Expired - Fee Related US8535904B2 (en) 2006-12-08 2012-05-21 Method of enhancing skin barrier function

Country Status (4)

Country Link
US (2) US20100068309A1 (en)
JP (1) JP2010511376A (en)
TW (1) TW200831125A (en)
WO (1) WO2008072717A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112107513A (en) * 2020-09-07 2020-12-22 中山大学·深圳 Anti-allergy composition and preparation method and application thereof
CN115282097A (en) * 2022-08-19 2022-11-04 澳宝化妆品(惠州)有限公司 Cyclobalanopsis glauca bark extract and skin care composition containing same

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009294202A (en) * 2008-05-09 2009-12-17 Pola Chem Ind Inc Differentiation method for involvement of tight junction in material transport
JP2009294200A (en) * 2008-05-09 2009-12-17 Pola Chem Ind Inc Differentiation method for tight junction function restoring agent
JP5406582B2 (en) * 2008-05-09 2014-02-05 ポーラ化成工業株式会社 Screening method for materials for improving multifaceted skin barrier function
JP2011162476A (en) * 2010-02-09 2011-08-25 Maruzen Pharmaceut Co Ltd SERINE PALMITOYLTRANSFERASE mRNA EXPRESSION PROMOTER AND AQUAPORIN 3 mRNA EXPRESSION PROMOTER
JP5737663B2 (en) * 2011-04-22 2015-06-17 大学共同利用機関法人自然科学研究機構 Skin barrier function improver
FR3042974B1 (en) * 2015-11-04 2017-12-08 Isp Investments Inc SYNERGISTIC EXTRACT OF PALMARIA PALMATA AND JASMIN, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF
TW202042780A (en) 2019-01-30 2020-12-01 德商巴地斯顏料化工廠 Cosmetic composition of liquid crystal lipid particles for personal care applications

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092855A1 (en) * 2000-10-02 2004-05-13 Tomas Fabo Self-adhesive wound dressing
US7169609B2 (en) * 2004-03-31 2007-01-30 Vertex Pharmaceutcals, Inc. Multiwell plate assembly for use in high throughput assays

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10172310A (en) * 1996-12-09 1998-06-26 Nissan Motor Co Ltd Display lamp for vehicle
JPH1129460A (en) * 1997-07-04 1999-02-02 Pola Chem Ind Inc Cosmetic for sensitive skin
JPH11302143A (en) * 1998-02-20 1999-11-02 Kanebo Ltd Enhancer of barrier strength against permeation through skin, and cosmetic
US6149924A (en) * 1998-07-20 2000-11-21 Biomed Research & Technologies, Inc. Composition for enhancing lipid production, barrier function, hydrogen peroxide neutralization, and moisturization of the skin
JP2000212028A (en) * 1999-01-27 2000-08-02 Pola Chem Ind Inc Preparation for external use for skin for treatment of stress disorder
WO2001026670A1 (en) * 1999-10-14 2001-04-19 The Nisshin Oil Mills, Ltd. Skin-care agents, skin antiaging agents, whitening agents and external skin preparations
JP2003514002A (en) * 1999-11-16 2003-04-15 ユニリーバー・ナームローゼ・ベンノートシヤープ Beauty composition containing anise extract and retinoid
JP2001240529A (en) * 2000-03-01 2001-09-04 Pola Chem Ind Inc Cosmetics for skin care
EP1610760A4 (en) * 2003-03-28 2008-01-09 Lonza Ag Topical l-carnitine compositions
US20050106116A1 (en) * 2003-11-19 2005-05-19 Smothers Donald L. Foot treatment method and composition
JP2007174931A (en) * 2005-12-27 2007-07-12 Pola Chem Ind Inc Epidermal keratinocyte layer membrane and utilization of the epidermal keratinocyte layer membrane
CN101460138B (en) * 2006-06-08 2011-07-20 味之素株式会社 Hair growth composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092855A1 (en) * 2000-10-02 2004-05-13 Tomas Fabo Self-adhesive wound dressing
US7169609B2 (en) * 2004-03-31 2007-01-30 Vertex Pharmaceutcals, Inc. Multiwell plate assembly for use in high throughput assays

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112107513A (en) * 2020-09-07 2020-12-22 中山大学·深圳 Anti-allergy composition and preparation method and application thereof
CN115282097A (en) * 2022-08-19 2022-11-04 澳宝化妆品(惠州)有限公司 Cyclobalanopsis glauca bark extract and skin care composition containing same

Also Published As

Publication number Publication date
JP2010511376A (en) 2010-04-15
US20120282357A1 (en) 2012-11-08
TW200831125A (en) 2008-08-01
WO2008072717A1 (en) 2008-06-19
US8535904B2 (en) 2013-09-17

Similar Documents

Publication Publication Date Title
US8535904B2 (en) Method of enhancing skin barrier function
Mashayekhi et al. Alteration of cyclic nucleotides levels and oxidative stress in saliva of human subjects with periodontitis
US20080269304A1 (en) Parakeratosis inhibitor, pore-shrinking agent and skin preparation for external use
Vater et al. Cytotoxicity of lecithin-based nanoemulsions on human skin cells and ex vivo skin permeation: Comparison to conventional surfactant types
KR20100138918A (en) Skin whitening method and screening method for factors for skin wrinkle formation suppression and/or removal
EP1987810B1 (en) External preparation for skin containing flavanone derivative
US20220160607A1 (en) Anti-aging cosmetic compositions
WO2007078034A1 (en) A composition for inhibiting the c-kit portein containing benzimidazole amine derivatives or aminoquinoline derivatives
US20050129618A1 (en) Drugs for ameliorating itch, rough skin or hypersensitive skin or for whitening via inhibition of the production and release of stem cell factor
Moors et al. Is the FAMACHA© chart suitable for every breed? Correlations between FAMACHA© scores and different traits of mucosa colour in naturally parasite infected sheep breeds
CN113384507A (en) Anti-aging composition and preparation method and application thereof
CN109381394A (en) A kind of skin antiallergic remediation composition and application
Satou et al. Toxocara canis: Search for a potential drug amongst β-carboline alkaloids—in vitro and mouse studies
Krishnamoorthy et al. Dano: A herbal solution for dandruff
EP3305370B1 (en) Algae autophagy activator
CN106880537B (en) Skin cell activity promoting effect of snow lotus herb extract and application of snow lotus herb extract in skin external preparation
JP2020094047A (en) Agents for improving or variegating normal bacterial flora of skin and compositions containing the same
JP4914029B2 (en) Type IV and type VII collagen production promoter
JP7237465B2 (en) A screening method using the expression levels of the occludin gene, the claudin gene, and the zo-1 gene under hypoxic conditions as an indicator, an inhibitor of claudin gene expression reduction, an inhibitor of cell adhesion apparatus function deterioration, and a reduction in skin barrier function ameliorating or preventive agent
AU2021252728A1 (en) Composition for suppressing cellular senescence, and method for suppressing cellular senescence
Harbell et al. Assessment of the cytosensor microphysiometer assay in the COLIPA in vitro eye irritation validation study
KUWAGATA et al. A comparison of the in vivo and in vitro response of rat embryos to 5-fluorouracil
KR101738340B1 (en) Composition for improving skin aging and wrinkle comprising Coptis teeta and Trichosanthes rosthornii mixed extract as effective component
Al-Kenani Detection of some immunological and biochemical markers in seborrheic dermatitis patients
US20230092216A1 (en) Active principle comprising a particular extract of punica granatum and uses for preventing and/or treating acne

Legal Events

Date Code Title Description
AS Assignment

Owner name: POLA CHEMICAL INDUSTRIES INC.,JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KURODA, SHOHEI;YAMAMOTO, TAKUYA;SAEKI, YUKO;AND OTHERS;SIGNING DATES FROM 20090309 TO 20090325;REEL/FRAME:022741/0558

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION